Brought to you by 
Wilex licenses Centocor's G250 cancer mAb
28 Oct 1999
Executive Summary
Munich-based cancer therapeutics start-up Wilex Biotechnology GMBH has licensed exclusive worldwide rights to Centocor's Phase I G250 monoclonal antibody to determine its therapeutic potential in renal cancer applications. Centocor has the option to market the product in the US, upon which it will pay Wilex an up-front payment in addition to milestones and profits on sales.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com